The overuse of antibiotics is widely recognized as one of the main factors contributing to antimicrobial resistance (AMR), often called the “silent pandemic,” but what is less well-known is that shortages of antibiotics also play a role in fueling it.
Scarce supplies of pediatric amoxicillin, used to treat Strep A, made headlines in the UK late last year, as a surge of infections left at least 19 children dead. From being an outlier, such shortfalls are common and pervasive, affecting countries across the world, and their consequences for individuals’ health and AMR’s spread can be dire.
That is because shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only can these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long-run.
Illustration: Mountain People
Already one of the world’s biggest killers, AMR is on the rise. In 2019, it was directly responsible for an estimated 1.27 million deaths — more than HIV/AIDS and malaria combined — and associated with 4.95 million more.
So far, the global response to this growing crisis has focused mainly on trying to outpace drug-resistant bacteria through the development of new antibiotics.
Yet in the short term, there is ample room to reduce the number of AMR deaths, as well as AMR’s impact on health more broadly, by addressing some of the causes of shortages and improving access to appropriate treatments.
The same market failures that triggered the global AMR crisis are also largely responsible for antibiotic shortages. Compared with other drugs, antibiotics are often more complex and more costly to manufacture, have stricter regulatory requirements and are less profitable. As a result, many pharmaceutical companies have significantly reduced or stopped antibiotic research and development over the past few decades.
Not only are very few new antibiotics being developed, but it has also become less attractive to produce those already on the market, partly due to supply chain bottlenecks and volatility. All it takes is a disruption in the supply of an ingredient or a quality-control problem, or a supplier increasing prices or halting production entirely, to bring the global supply chain of these medicines to a standstill.
Just as important has been the equally volatile demand for antibiotics caused by sudden outbreaks of bacterial infections and poor management of national supplies, which contributes to stockouts. While shortages are not uncommon in the pharmaceutical industry, they are 42 percent more likely for antibiotics than they are for other drugs.
Although precise numbers that would reveal the scale of the problem are difficult to obtain, much of this uncertainty could be avoided with better market intelligence. Even though antibiotics are less lucrative than other drugs, pharmaceutical companies can still turn a profit — if they have accurate data. Improved forecasting can thus reduce risks for manufacturers and provide them with an incentive to scale up production and expand their markets.
There is also plenty of room for improvement in the way that countries — particularly lower-income nations — procure, register and manage these vital drugs.
For example, by expanding the capacity of national regulatory authorities, it would be easier to track and coordinate supplies and create stockpiles to build greater resilience. All of this would also help provide more certainty for drugmakers.
SECURE, an initiative led by the WHO and the Global Antibiotic Research and Development Partnership (of which I am executive director), aims to work with countries to improve access to essential antibiotics. That involves exploring how national regulatory authorities could serve as centralized hubs to help monitor, prevent and respond to shortages.
Eventually, SECURE intends to create more buoyant and competitive markets by encouraging countries to pool procurement, ensuring a more reliable supply.
Shortages of antibiotics are a serious problem for all countries, but there is plenty that can — and should — be done to prevent them. Given the accelerating spread of AMR and the long lead-in time to develop antibiotics, the problem can no longer be overlooked.
Equally important, efforts to address scarce supplies could help ensure that, when new drugs become available, they reach the people who need them.
Manica Balasegaram is executive director of the Global Antibiotic Research and Development Partnership.
Copyright: Project Syndicate
The gutting of Voice of America (VOA) and Radio Free Asia (RFA) by US President Donald Trump’s administration poses a serious threat to the global voice of freedom, particularly for those living under authoritarian regimes such as China. The US — hailed as the model of liberal democracy — has the moral responsibility to uphold the values it champions. In undermining these institutions, the US risks diminishing its “soft power,” a pivotal pillar of its global influence. VOA Tibetan and RFA Tibetan played an enormous role in promoting the strong image of the US in and outside Tibet. On VOA Tibetan,
Sung Chien-liang (宋建樑), the leader of the Chinese Nationalist Party’s (KMT) efforts to recall Democratic Progressive Party (DPP) Legislator Lee Kun-cheng (李坤城), caused a national outrage and drew diplomatic condemnation on Tuesday after he arrived at the New Taipei City District Prosecutors’ Office dressed in a Nazi uniform. Sung performed a Nazi salute and carried a copy of Adolf Hitler’s Mein Kampf as he arrived to be questioned over allegations of signature forgery in the recall petition. The KMT’s response to the incident has shown a striking lack of contrition and decency. Rather than apologizing and distancing itself from Sung’s actions,
US President Trump weighed into the state of America’s semiconductor manufacturing when he declared, “They [Taiwan] stole it from us. They took it from us, and I don’t blame them. I give them credit.” At a prior White House event President Trump hosted TSMC chairman C.C. Wei (魏哲家), head of the world’s largest and most advanced chip manufacturer, to announce a commitment to invest US$100 billion in America. The president then shifted his previously critical rhetoric on Taiwan and put off tariffs on its chips. Now we learn that the Trump Administration is conducting a “trade investigation” on semiconductors which
By now, most of Taiwan has heard Taipei Mayor Chiang Wan-an’s (蔣萬安) threats to initiate a vote of no confidence against the Cabinet. His rationale is that the Democratic Progressive Party (DPP)-led government’s investigation into alleged signature forgery in the Chinese Nationalist Party’s (KMT) recall campaign constitutes “political persecution.” I sincerely hope he goes through with it. The opposition currently holds a majority in the Legislative Yuan, so the initiation of a no-confidence motion and its passage should be entirely within reach. If Chiang truly believes that the government is overreaching, abusing its power and targeting political opponents — then
RSS